Compare Ginkgo Bioworks Holdings Inc (DNA) vs Iron Mountain Inc (IRM) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.

The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.

Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong analyst consensus. The company reported revenue growth to $6.90B in 2025, though net income margin compressed to 2.09%. Recent news highlights expansion in data centers and digital partnerships, while institutional investors like Bank of America and California State Teachers Retirement System increased holdings significantly in Q2 2026.

The outlook remains positive with a consensus price target of $142.75 implying 23% upside, supported by data center pipeline growth and digital cross-selling. Key risks include high debt levels with a debt-to-asset ratio of 79.04% in 2025 and margin pressure from rising interest expenses. Earnings beats in recent quarters reinforce execution strength, but valuation multiples like a P/E of 82.09 demand sustained growth.